Tafolecimab and sintilimab plus chemo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IIIB–IV) non-small cell lung cancer that has gotten worse after first-line treatment with an immunotherapy drug like Keytruda or Opdivo.
- Your tumor does not have an EGFR or ALK gene mutation (these are usually treated with other drugs).
- You are between 18 and 75 years old, and your general health is good (ECOG score 0 or 1 – meaning you are quite active).
- You must have at least one tumor that can be measured on a CT or MRI scan.
- If the cancer has spread to your brain, it must be stable (not causing new problems) and controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new combination for advanced lung cancer: an immunotherapy drug (tislelizumab) plus standard chemotherapy, and adds a common allergy medicine (diphenhydramine) to see if it improves outcomes. It's for people who haven't had prior systemic treatment for their lung cancer and are generally healthy.
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer. The drugs aim to help your immune system fight the cancer more effectively.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial tests a new combination of three drugs for people with advanced non-small cell lung cancer that has grown despite previous immunotherapy. The goal is to see if adding these drugs can help control the cancer better.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.